Tempest Therapeutics (TPST) said Monday the US Food and Drug Administration granted fast track designation to amezalpat for the potential treatment of hepatocellular carcinoma, a type of liver cancer.
The company said the designation allows for increased communication with the FDA and potential eligibility for accelerated approval and priority review. The designation follows an orphan drug designation in January, Tempest added.
Tempest said amezalpat is being evaluated in combination with atezolizumab and bevacizumab in a global phase 1b/2 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Shares of the company were up 1.8% in recent Monday trading.
Price: 0.89, Change: +0.02, Percent Change: +1.77
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。